Scientific article

Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells

Published inCancer research, vol. 63, no. 2, p. 534-540
Publication date2003

Incubation of Burkitt lymphoma-derived Raji cells at physiological temperature with submicromolar concentrations of humanized anti-CD20 antibody rituximab (RTX) redistributes CD20 to liquid-ordered, plasma membrane rafts. This accumulation of the CD20 tetraspan protein in rafts does not change the existing lipid and phosphoprotein composition but makes sphingolipids and the Src regulator Cbp/PAG (Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomain) transmembrane phosphoprotein more resistant to n-octyl-beta-pyranoside, a detergent that dissociates sphingolipid clusters. On the contrary, sphingolipids and Cbp/PAG are not protected by the presence of CD20 against the disruptive effects of methyl-beta-cyclodextrin, a cyclic carbohydrate that removes membrane cholesterol. After accumulation of CD20, the activity of the raft-associated Lyn kinase is down-regulated without apparent alteration of its relationship to substrates. Moreover, in rafts of lymphoblastoid cells that express lower amounts of Cbp/PAG, RTX redistributes CD20 to rafts but does not modulate the raft-associated protein tyrosine kinase activity, suggesting that the presence of Cbp/PAG protein in rafts is necessary for RTX to exert its transmembrane "signaling effects." Lastly, redistribution of CD20 in rafts renders the glycosylphosphatidyl inositol (GPI)-linked CD55 C'-defense protein hypersensitive to glycosylphosphatidyl inositol-specific phospholipases. By redistributing CD20 to rafts, RTX modifies their stability and organization and modulates the associated signaling pathways and C' defense capacity.

  • Antibodies, Monoclonal/ pharmacology
  • Antigens, CD20/ metabolism
  • Antigens, CD55/metabolism
  • Antineoplastic Agents/ pharmacology
  • Cyclodextrins/chemistry
  • Glucosides/chemistry
  • Humans
  • Lymphoma, B-Cell/drug therapy/ metabolism
  • Membrane Lipids/metabolism
  • Membrane Microdomains/drug effects/ metabolism
  • Membrane Proteins/metabolism
  • Phospholipase D/metabolism
  • Phosphoproteins/metabolism
  • Type C Phospholipases/metabolism
  • beta-Cyclodextrins
  • src-Family Kinases/metabolism
Affiliation Not a UNIGE publication
Citation (ISO format)
SEMAC, Isabelle et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. In: Cancer research, 2003, vol. 63, n° 2, p. 534–540.
Main files (1)
ISSN of the journal0008-5472

Technical informations

Creation08/27/2010 1:36:10 PM
First validation08/27/2010 1:36:10 PM
Update time03/14/2023 4:05:16 PM
Status update03/14/2023 4:05:16 PM
Last indexation02/12/2024 7:24:01 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack